Jason A Heth
Clinical Professor of Neurosurgery
Clinical Professor of Otolaryngology-Head and Neck Surgery
Residency Assistant Director
Co-Director
CNS Tumor Registry and Medical Student Clerkship
[email protected]

Available to mentor

Jason A Heth
Clinical Professor
  • About
  • Qualifications
  • Research Overview
  • Recent Publications
  • About

    Dr. Heth joined the faculty at the University of Michigan Department of Neurosurgery in 2003. He was born in Iowa and primarily grew up in Iowa City. He attended the Johns Hopkins University and graduated with an undergraduate degree in Biomedical Engineering. He went to the University of Iowa for medical school and then residency. After spending a year in fellowship training with Osama Al-Mefty, MD, a pioneer in the field of skull base neurosurgery, Dr. Heth joined the faculty in 2003. He specializes in brain tumor surgery with particular interests in brain metastasis from systemic cancers, the effects of radiation treatment on the brain and brain metastasis, meningiomas, and skull base tumors. He has developed a strong interest in education and is very involved in medical student education, some specialized undergraduate programs, and residency training.

    Qualifications
    • Fellowship
      University of Arkansas for Medical Sciences, Neurosurgery, 2003
    Research Overview

    Brain metastasis and radiation necrosis/treatment effects on the CNS
    Educational initiatives in medical students and undergraduate students, particularly "first in family" students

    Recent Publications See All Publications
    • Journal Article
      Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion.
      Serhan HA, Bao L, Cheng X, Qin Z, Liu C-J, Heth JA, Udager AM, Soellner MB, Merajver SD, Morikawa A, Merrill NM. NPJ Breast Cancer, 2024 Jun 10; 10 (1): 43 DOI:10.1038/s41523-024-00656-0
      PMID: 38858374
    • Proceeding / Abstract / Poster
      Examining molecular landscape and drug sensitivity profiles of patient-derived xenografts from resected brain metastases.
      Morikawa A, Rastogi T, Ulintz P, Serhan H, Nieblas-Bedolla E, Heth J, Cheng X, Bao L, Udager AM, Soellner M, Merrill N, Merajver SD. Journal of Clinical Oncology, 2024 Aug 10; 42 (23_suppl): 28 - 28. DOI:10.1200/jco.2024.42.23_suppl.28
    • Journal Article
      AB036. Targeting glioblastoma de-novo purine metabolism to overcome chemoradiation resistance: an interim result of phase 0/1 clinical trial in newly diagnosed and recurrent glioblastoma.
      Umemura Y, Clarke N, Al-Holou W, Elaimy A, Scott A, Leung D, Kim M, Ferris S, Thomas J, Heth J, Schipper M, Suresh K, Lawrence T, Wahl D. Chin Clin Oncol, 2024 Aug; 13 (Suppl 1): AB036 DOI:10.21037/cco-24-ab036
      PMID: 39295354
    • Presentation
      Evolution of Standardized Letters of Evaluation: Progress?
      Heth J. 2024 May 19;
    • Journal Article
      Abstract B051: DNA damage signaling activates GTP synthesis to promote glioblastoma treatment resistance
      Scott AJ, O'Brien A, Zhou W, Xu J, Palavalasa S, Kothari AU, Wilder-Romans K, Zhang L, Andren AC, Chandrasekaran S, Heth J, Umemura Y, Qi N, Lawrence TS, Al-Holou WN, Lyssiotis CA, Wahl DR. Cancer Research, 2024 Mar 4; 84 (5_Supplement_1): b051 - b051. DOI:10.1158/1538-7445.brain23-b051
    • Journal Article
      Milestones for neurosurgery sub-interns: a novel evaluation tool to quantitatively differentiate residency applicants.
      Bowden SG, Tan H, Rothbaum MG, Cook SH, Hanft S, Heth J, Morgenstern PF, Mullin JP, Orina JN, Wilson JL, Winer JL, Wolfe SQ, Chambless LB, Selden NR. J Neurosurg, 2023 Dec 1; 139 (6): 1748 - 1756. DOI:10.3171/2023.3.JNS23259
      PMID: 37148230
    • Journal Article
      BIOM-58. ZERO-WASTE MOLECULAR DIAGNOSTICS FROM BIOPSY NEEDLE WASHES
      Wadden J, John V, Niculcea M, Kong S, Aittaleb R, Cartaxo R, Verbal K, Bruzek A, Magge S, Yadavilli S, Erez N, Furth N, Shema E, Marapudi N, Heth J, Al-holou W, Garton H, Nazarian J, Koschmann C. Neuro-Oncology, 2023 Nov 10; 25 (Supplement_5): v17 - v18. DOI:10.1093/neuonc/noad179.0069
    • Proceeding / Abstract / Poster
      CTNI-61. MYCOPHENOLATE MOFETIL INHIBITS GLIOBLASTOMA PURINE METABOLISM IN HUMANS: AN INTERIM RESULT OF PHASE 0/1 CLINICAL TRIAL TO OVERCOME TREATMENT RESISTANCE IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
      Umemura Y, Al-Holou W, Elaimy A, Scott AJ, Leung D, Clarke N, Kim MM, Ferris S, Thomas J, Heth J, Schipper M, Suresh K, Lawrence T, Wahl D. Neuro-Oncology, 2023 Nov 10; 25 (Supplement_5): v90 - v90. DOI:10.1093/neuonc/noad179.0343